Bexagliflozin

Bexagliflozin
Names
Trade namesBrenzavvy, Bexacat
IUPAC name
  • (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Clinical data
Drug classSGLT2 inhibitor[1]
Main usesType 2 diabetes[1]
Side effectsVaginal yeast infections, urinary tract infections, increased urination[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		By mouth
Typical dose20 mg OD[1]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
Chemical and physical data
FormulaC24H29ClO7
Molar mass464.94 g·mol−1
3D model (JSmol)
SMILES
  • C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
InChI
  • InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1
  • Key:BTCRKOKVYTVOLU-SJSRKZJXSA-N

Bexagliflozin, sold under the brand name Brenzavvy among others, is a medication used to treat type 2 diabetes.[1] It is used with diet and exercise.[1] It is taken by mouth.[1]

Common side effects include vaginal yeast infections, urinary tract infections, and increased urination.[1] Serious side effects may include diabetic ketoacidosis, limb amputation, low blood sugar, Fournier’s gangrene, and kidney problems.[1] Use is not recommended during the latter part of pregnancy.[1] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.[1]

Bexagliflozin was approved for medical use in the United States in 2023.[1] The cost in the United States was not clear as of early 2023.[4]

Medical uses

Bexagliflozin is used to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.[5] Other benefits may include decreased wight and blood pressure.[4]


Dosage

It is generally taken at a dose of 20 mg once per day.[1]

Research

A 96-week phase 2 clinical study of adults with type 2 diabetes showed that bexagliflozin monotherapy provided a durable, clinically meaningful improvement of glycemic control, with a substantial reduction in weight and blood pressure, but no increase in the rate of significant adverse events.[6][7] In a clinical study of patients with type 2 diabetes and stage 3a/3b chronic kidney disease, bexagliflozin was well tolerated and shown to reduce hemoglobin A1c levels, body weight, systolic blood pressure and albuminuria.[8]

Other animals

The data from two six-month field studies and an extended use field study demonstrated that bexagliflozin was over 80% effective in improving glycemic control in cats with diabetes mellitus.[3]

Bexagliflozin, sold under the brand name Bexacat, is an antidiabetic medication used to improve glycemic control in cats with diabetes.[3] Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species.[3] It was approved for medical use in the United States in December 2022.[3][9] Bexacat is sponsored by Increvet Inc., based in Boston, Massachusetts.[3] Elanco licensed development and commercialization rights for bexagliflozin from Bexcafe, an affiliate of Increvet.[9]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Archive copy" (PDF). Archived (PDF) from the original on 2023-03-06. Retrieved 2023-03-07.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ↑ "Bexacat- bexagliflozin tablets tablet". DailyMed. 16 January 2023. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
  3. 1 2 3 4 5 6 "FDA Approves First Oral Treatment for Cats with Diabetes Mellitus". U.S. Food and Drug Administration (FDA). 8 December 2022. Archived from the original on 11 December 2022. Retrieved 11 December 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  4. 1 2 "FDA Approves New Drug for Type 2 Diabetes". Formulary Watch. Archived from the original on 7 February 2023. Retrieved 1 May 2023.
  5. ↑ "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 20 January 2023. Archived from the original on 21 January 2023. Retrieved 21 January 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ↑ Halvorsen YD, Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, et al. (September 2022). "A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults". Diabetes, Obesity and Metabolism. 25 (1): 293–301. doi:10.1111/dom.14875. PMID 36178197. S2CID 252623503.
  7. ↑ Halvorsen YC, Walford GA, Massaro J, Aftring RP, Freeman MW (November 2019). "A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes". Diabetes, Obesity and Metabolism. 21 (11): 2496–2504. doi:10.1111/dom.13833. PMID 31297965. S2CID 195892291.
  8. ↑ Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, et al. (September 2019). "Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD". American Journal of Kidney Diseases. 74 (3): 328–337. doi:10.1053/j.ajkd.2019.03.417. PMID 31101403. S2CID 157066958.
  9. 1 2 "Elanco Announces FDA Approval of Bexacat (bexagliflozin tablets) – the First-of-its-Kind Oral Feline Diabetes Treatment Option" (Press release). Elanco. 9 December 2022. Archived from the original on 11 December 2022. Retrieved 11 December 2022.

Further reading

External sites:
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.